Zydus Lifesciences Limited has received tentative approval from the United States Food and Drug Administration (USFDA) to market Diroximel Fumarate Delayed-Release Capsules, 231 mg (USRLD: Vumerity Delayed-Release Capsules tablets). Diroximel Fumate Delayed-Release Capsules is indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults. The drug will be manufactured at the group's formulation manufacturing facility in Ahmedabad SEZ, India.

Diroximel Fumar Delayed-Release Capsules had annual sales of USD 847.4 million in the United States (IQVIA MAT May 2024). The group now has 398 approvals and has so far filed over 460 ANDAs since the commencement of the filing process in Fiscal Year 2003-04.